In the context of HCC, it has been suggested that defective TGF-β signalling promotes tumourigenesis secondary to reduced responsiveness to the anti-proliferative effects of TGF-β signalling [103, 104]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.